Efficacy of apremilast in hyperkeratotic hand and foot dermatitis: results from a randomized observer-blinded comparative study.

Autor: Bhat K; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Patra S; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Bhardwaj A; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Singh S; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Budania A; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Bains A; Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodhpur, Jodhpur, India., Saurabh S; Department of Community Medicine And Family Medicine, All India Institute of Medical Sciences Jodhpur, Jodhpur, India.
Jazyk: angličtina
Zdroj: International journal of dermatology [Int J Dermatol] 2024 Nov; Vol. 63 (11), pp. 1535-1540. Date of Electronic Publication: 2024 May 17.
DOI: 10.1111/ijd.17185
Abstrakt: Background: Hyperkeratotic hand and foot dermatitis significantly affects quality of life. Some patients respond suboptimally to topical corticosteroids and have multiple recurrences.
Objective: Our aim was to compare the efficacy and safety profile of apremilast and topical corticosteroid versus corticosteroid alone in hyperkeratotic hand and foot dermatitis.
Methods: This randomized controlled study involved 77 patients treated for 3 months. Group A (39 patients) received mometasone furoate 0.1% cream with oral apremilast 30 mg twice daily, and Group B (38 patients) received mometasone alone. They were assessed monthly using the Hand Eczema Clinical Severity Index (HECSI) and Visual Analogue Scale (VAS) scores for pruritus. Investigator Global Assessment (IGA) and Quality of Life in Hand Eczema Questionnaire (QOLHEQ) were conducted at the end of 3 months.
Results: The HECSI, VAS score, and QOLHEQ showed a significant decrease in both groups from baseline to the third month. Intergroup comparisons of HECSI failed to reach the significance level. When compared, patients receiving apremilast had significantly better improvement in the third month according to the Patient Global Assessment (PGA) and Investigator Global Assessment (IGA). They also had a smaller number of flares.
Conclusion: Adding apremilast to topical corticosteroid leads to better patient and physician-perceived improvement and reduces the number of flares in hyperkeratotic hand eczema.
(© 2024 the International Society of Dermatology.)
Databáze: MEDLINE
Externí odkaz: